A mental disorder, also referred to as a mental illness, a mental health condition, or a psychiatric disorder, is a behavioral or mental pattern that causes significant distress or impairment of personal functioning. A mental disorder is also characterized by a clinically significant disturbance in an individual's cognition, emotional regulation, or behavior, often in a social context. Such disturbances may occur as single episodes, may be persistent, or may be relapsing–remitting. There are many different types of mental disorders, with signs and symptoms that vary widely between specific disorders. A mental disorder is one aspect of mental health.
Kava or kava kava is a crop of the Pacific Islands. The name kava is from Tongan and Marquesan, meaning 'bitter'; other names for kava include ʻawa (Hawaiʻi), ʻava (Samoa), yaqona or yagona (Fiji), sakau (Pohnpei), seka (Kosrae), and malok or malogu. Kava is consumed for its sedating effects throughout the Pacific Ocean cultures of Polynesia, including Hawaii and Vanuatu, Melanesia, some parts of Micronesia, such as Pohnpei and Kosrae, and the Philippines.
A psychiatric or psychotropic medication is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus, these medications are used to treat mental illnesses. These medications are typically made of synthetic chemical compounds and are usually prescribed in psychiatric settings, potentially involuntarily during commitment. Since the mid-20th century, such medications have been leading treatments for a broad range of mental disorders and have decreased the need for long-term hospitalization, thereby lowering the cost of mental health care. The recidivism or rehospitalization of the mentally ill is at a high rate in many countries, and the reasons for the relapses are under research.
Kavalactones are a class of lactone compounds found in kava roots and Alpinia zerumbet. Some kavalactones are bioactive.
Psychedelic therapy refers to the proposed use of psychedelic drugs, such as psilocybin, MDMA, LSD, and ayahuasca, to treat mental disorders. As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials, with some exceptions.
The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) is a leading centre for mental health and neuroscience research, education and training in Europe. It is dedicated to understanding, preventing and treating mental illness, neurological conditions, and other conditions that affect the brain. The IoPPN is a faculty of King's College London, England, and was previously known as the Institute of Psychiatry (IoP).
Gordon Barraclough Parker AO is an Australian psychiatrist who is scientia professor of psychiatry at the University of New South Wales (UNSW).
The Mental Health Research Institute (MHRI) is a former Australian medical research institute that was focused upon improving the diagnosis, treatment and prevention of major mental disorders. The MHRI was active between 1956 and 2012, when it was merged with the Florey Neuroscience Institutes to form the Florey Institute of Neuroscience and Mental Health. Based in Melbourne, Victoria, the research efforts of the MHRI were focused on understanding schizophrenia, bipolar and major mood disorders, and Alzheimer's disease.
Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.
Kevin Joseph Michael Gournay CBE FMedSci FRCN FRSM FRCPsych (Hon) PhD RN CSci Cert CBT is a registered psychologist, chartered scientist and a registered nurse by background. He is an emeritus professor at the Institute of Psychiatry, King's College London. He was a consultant psychologist at the Priory Hospital North London; retiring in December 2018. He has now returned to clinical work as part of the response to COVID19. He is currently an Honorary Professor at the Matilda Centre; University of Sydney., where his work focusses on the impact of COVID19 on mental health and the combination of mental health problems and substance use. He has been responsible over many years for a very wide range of research, policy and practice development in mental health care. He also works as an Expert Witness; he has provided reports on more than 300 suicides; 20 homicides and hundreds of reports on people who have suffered the consequences of traumatic events, including accidents, terrorist related incidents, natural disasters, war related events and stillbirth and perinatal death. He has also provided numerous reports on patients receiving care and treatment in high secure and Medium secure settings, including Broadmoor, Rampton and Ashworth hospitals
The Black Dog Institute is a not-for-profit facility for diagnosis, treatment and prevention of mood disorders such as depression, anxiety and bipolar disorder. It was founded in 2002 by the UNSW School of Psychiatry Scientia Professor Gordon Parker and is based in Sydney, Australia.
Philip Manley Boyce is an Australian psychiatrist. He is an Emeritus Professor of Psychiatry at the University of Sydney and an Emeritus Consultant in Psychiatry at Westmead Hospital. He was a professor of psychiatry and head of discipline of psychiatry at the University of Sydney, and head of Perinatal Psychiatry Clinical Research Unit at Westmead Hospital. He has published more than 350 articles, and frequently contributes to psychiatric textbooks. He served as associate editor of Australian and New Zealand Journal of Psychiatry. He has a long clinical and research interest in anxiety disorders, mood disorders, psychosomatic disorders, and perinatal psychiatry. He has also taken leadership roles in the profession as president of the RANZCP and the international Marcé society, in the development of clinical practice guidelines, and in the development of a competency-based training program for the college.
Louise Newman is an Australian developmental psychiatrist and clinical researcher currently based at Monash University, in Melbourne, Australia. She is an advocate for the mental health of asylum seekers.
Richard Allan Bryant is an Australian medical scientist. He is Scientia Professor of Psychology at the University of New South Wales (UNSW) and director of the UNSW Traumatic Stress Clinic, based at UNSW and Westmead Institute for Medical Research. His main areas of research are posttraumatic stress disorder (PTSD) and prolonged grief disorder. On 13 June 2016 he was appointed a Companion of the Order of Australia (AC), for eminent service to medical research in the field of psychotraumatology, as a psychologist and author, to the study of Indigenous mental health, as an advisor to a range of government and international organisations, and to professional societies.
Michael or Mike Kyrios is a Greek-Australian clinical psychologist. He is an emeritus professor at Flinders University, after serving as vice-president and executive dean at the university's College of Education, Psychology and Social Work.
Charles Grob is a professor of Psychiatry & Biobehavioral Sciences and Pediatrics and director of the Division of Child and Adolescent Psychiatry at Harbor–UCLA Medical Center. He received his two BS degrees from Oberlin College and Columbia University, before getting an MD from the State University of New York, Downstate Medical Center. Grob's research interests include anxiety and mood disorders and also self-medication and substance abuse. The FDA approved one of his Phase 1 studies to study the psychological and physiological effects of MDMA and the hallucinogen ayahuasca.
Julia Rucklidge is a Canadian-born clinical psychologist who is the director of the Mental Health and Nutrition Research Group at the University of Canterbury in New Zealand. Her research has centered on mental health and nutrition.
Psilocybin therapy is the use of psilocybin in treating a range of mental health conditions, such as depression, anxiety, addictions, obsessive compulsive disorder, and psychosis. It is one of several forms of psychedelic therapy under study. Psilocybin was popularized as a psychedelic recreational drug in the 1970s and was classified as a Schedule I drug by the DEA. Research on psilocybin as a medical treatment was restricted until the 1990s because of the sociocultural fear of dependence on this drug. As of 2022, psilocybin is the most commonly researched psychedelic due to its safety and low potential for abuse and dependence. Clinical trials are being conducted at universities and there is evidence confirming the use of psilocybin in the treatment of depression, PTSD and end of life anxiety.
MDMA-assisted psychotherapy is the use of prescribed doses of MDMA as an adjunct to psychotherapy sessions. Research suggests that MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD), including Complex PTSD, might improve treatment effectiveness. In 2017, a Phase II clinical trial led to "breakthrough therapy" designation by the US Food and Drug Administration (FDA) for potential use as a treatment for PTSD.
Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.
